14 studies found for:
"RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Genital Diseases, Female"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
|
||||
| 2 | Recruiting |
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
|
||||
| 3 | Recruiting |
Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
|
||||
| 4 | Unknown † |
AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
|
||||
| 5 | Recruiting |
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
|
||||
| 6 | Unknown † |
Intraperitoneal Paclitaxel, Doxorubicin, and Cisplatin in Treating Patients With Endometrial Cancer
|
||||
| 7 | Recruiting |
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
|
||||
| 8 | Recruiting |
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
|
||||
| 9 | Recruiting |
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
|
||||
| 10 | Recruiting |
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
|
||||
| 11 | Recruiting |
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
|
||||
| 12 | Recruiting |
Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
|
||||
| 13 | Recruiting |
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
|
||||
| 14 | Recruiting |
A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
|
† Indicates status has not been verified in more than two years